Home/Pipeline/Wixela Inhub (Fluticasone/Salmeterol)

Wixela Inhub (Fluticasone/Salmeterol)

Asthma, COPD

LaunchedMarketed (US, Authorized Generic)N/A

Key Facts

Indication

Asthma, COPD

Phase

Launched

Status

Marketed (US, Authorized Generic)

Company

Viatris

About Viatris

Viatris is a mission-driven global healthcare company formed in 2020 to empower people worldwide to live healthier lives through expanded access to medicines. Its strategy is built on four complementary pillars—generics, complex generics, biosimilars, and established brands—enabling it to deliver a broad portfolio across therapeutic areas and economic spectrums. The company has established itself as a leader in biosimilars and complex generics, managing a significant pipeline of 247 candidates while executing a strategic transformation to optimize its portfolio and drive sustainable growth through 2030.

View full company profile

Therapeutic Areas

Cardiology Dermatology Immunology Infectious Diseases Central Nervous System Disorders Oncology Respiratory

Other Asthma, COPD Drugs

Drug	Company	Phase	Status
HBM9378 (SKB378/WIN378)	Harbour BioMed	Phase 1	Active (Greater China)
HP-Betadex DPI Formulations	Aquilon Pharmaceuticals	Clinical	Active
Asthma vs. COPD Discrimination	The eNose Company	Clinical Development	Active
Generic Advair (Fluticasone/Salmeterol)	Lupin Limited	ANDA Filed/Approved	Active
Respiratory Inhalation Portfolio (Generic)	Cipla	ANDA Filed/Approved	Active
RELVAR/BREO ELLIPTA	Innoviva	Commercial	Royalty Revenue Generating